Kiniksa Pharmaceuticals International, plc Board of Directors

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.

Mr. Sanj K. Patel

Mr. Sanj K. Patel

CEO & Chairman of the Board

Ms. Mei Jang

Ms. Mei Jang

Senior Vice President of Technical Operations

Ms. Martina Struck Ph.D.

Ms. Martina Struck Ph.D.

Senior Vice President of Regulatory Affairs

Ms. Madelyn Demsky Zeylikman

Ms. Madelyn Demsky Zeylikman

SVP, General Counsel & Secretary

Dr. John F. Paolini FACC, M.D., Ph.D.

Dr. John F. Paolini FACC, M.D., Ph.D.

Senior VP & Chief Medical Officer

Mr. Carsten Boess M.B.A.

Mr. Carsten Boess M.B.A.

Executive Vice President of Corporate Affairs

Mr. Michael R. Megna CPA

Mr. Michael R. Megna CPA

Chief Accounting Officer & Group VP of Finance

Mr. Chad Morin

Mr. Chad Morin

Senior VP & Chief Compliance Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.